Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 March 2013Website:
http://www.enanta.comNext earnings report:
07 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 22 Nov 2024 22:29:31 GMTDividend
Analysts recommendations
Institutional Ownership
ENTA Latest News
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV.
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.86 per share a year ago.
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Enanta Pharmaceuticals (ENTA) reported a quarterly loss of $1.47 per share, which was higher than the Zacks Consensus Estimate of a loss of $1.26 per share. This is an improvement from the loss of $1.79 per share reported in the same quarter last year.
Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to loss of $1.39 per share a year ago.
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Enanta Pharmaceuticals (ENTA), OneConnect Financial. (OCFT), KNOT Offshore (KNOP), Hippo Holdings (HIPO) and H World Group (HTHT) could surprise investors with big returns this Christmas.
The mean of analysts' price targets for Enanta Pharmaceuticals (ENTA) points to an 88.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What type of business is Enanta Pharmaceuticals?
Enanta Pharmaceuticals, Inc. is an American biotechnology company specializing in the development of small molecule drugs for viral infections and liver diseases. The company was founded in 2004 and is headquartered in Hayward, California, USA. Enanta Pharmaceuticals is conducting clinical development in the following areas: RSV (respiratory syncytial virus). RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lungs) and pneumonia in children under one year of age in the United States. NASH (non-alcoholic steatohepatitis). HBV (hepatitis B virus) - a potentially life-threatening liver infection.
What sector is Enanta Pharmaceuticals in?
Enanta Pharmaceuticals is in the Healthcare sector
What industry is Enanta Pharmaceuticals in?
Enanta Pharmaceuticals is in the Biotechnology industry
What country is Enanta Pharmaceuticals from?
Enanta Pharmaceuticals is headquartered in United States
When did Enanta Pharmaceuticals go public?
Enanta Pharmaceuticals initial public offering (IPO) was on 21 March 2013
What is Enanta Pharmaceuticals website?
https://www.enanta.com
Is Enanta Pharmaceuticals in the S&P 500?
No, Enanta Pharmaceuticals is not included in the S&P 500 index
Is Enanta Pharmaceuticals in the NASDAQ 100?
No, Enanta Pharmaceuticals is not included in the NASDAQ 100 index
Is Enanta Pharmaceuticals in the Dow Jones?
No, Enanta Pharmaceuticals is not included in the Dow Jones index
When was Enanta Pharmaceuticals the previous earnings report?
No data
When does Enanta Pharmaceuticals earnings report?
The next expected earnings date for Enanta Pharmaceuticals is 07 February 2025